Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: Implications for vaccine design

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4688-4692

  Bonsignori, Mattia ^a   Montefiori, David C ^a,c   Wu, Xueling ^h   Chen, Xi ^a   Hwang, Kwan Ki ^a   Tsao, Chun Yen ^a   Kozink, Daniel M ^a   Parks, Robert J ^a   Tomaras, Georgia D ^a,c   Crump, John A ^a,b,e,f   Kapiga, Saidi H ^g   Sam, Noel E ^e   Kwong, Peter D ^h   Kepler, Thomas B ^a,d   Liao, Hua Xin ^a   Mascola, John R ^h   Haynes, Barton F ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

^c Department of Surgery ^*  (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^f KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH01; MONOCLONAL ANTIBODY VRC CH31; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL LINEAGE; CELL SELECTION; CELL SPECIFICITY; CLONAL VARIATION; CONTROLLED STUDY; DRUG DESIGN; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF DETECTION; MEMORY CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENS, CD4; B-LYMPHOCYTES; BINDING SITES; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; NEUTRALIZATION TESTS; PHYLOGENY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860723906     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07163-11     Document Type: Article

References (26)

1. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
2. Bonsignori M, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
3. Burton DR, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
4. Doria-Rose NA, et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
5. Gray ES, et al. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840.
6. Gray ES, et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83:8925-8937.
7. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. 1991. Sequences of proteins of immunological interest, 5th ed. National Institutes of Health, US Department of Health and Human Services, Bethesda, MD.
8. Li Y, et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85:8954-8967.
9. Li Y, et al. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059.
10. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554.
11. Montefiori DC. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 2005:12.11.1-12.11.17.
12. Mouquet H, et al. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467:591-595.
13. Muster T, et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
14. Pancera M, et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84: 8098-8110.
15. Pejchal R, et al. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 107:11483-11488.
16. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
17. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
18. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
19. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870.
20. Tomaras GD, et al. 2011. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85:11502-11519.
21. Trkola A, et al. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
22. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
23. Walker LM, et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028.
24. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
25. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing. Science 333:1593-1602.
26. Zwick MB, et al. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.